Skip to main content
NCBI home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2003 Dec;80(4):667–675. doi: 10.1093/jurban/jtg073

Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy

Anita Palepu 1,✉, Mark W Tyndall 1, Kathy Li 1, Benita Yip 1, Michael V O’Shaughnessy 1, Martin T Schechter 1, Julio S G Montaner 1, Robert S Hogg 1
PMCID: PMC3456224  PMID: 14709714

Abstract

We conducted this study among HIV-infected injection drug users to determine the effect of self-reported alcohol use and prior incarceration at the time of initiating antiretroviral therapy on subsequent HIV-1 RNA suppression. We examined the demographics, recent incarceration history, and drug and alcohol use history from the Vancouver Injection Drug User Study (VIDUS) questionnaire closest to the date of initiating antiretroviral therapy. We linked these data to the HIV/AIDS Drug Treatment Program. There were 234 VIDUS participants who accessed antiretroviral therapy through the Drug Treatment Program from August 1, 1996, to July 31, 2001. In terms of illicit drug use, 196 (84%) reported injecting heroin and cocaine at the time of initiating antiretroviral therapy. Multiple logistic regression revealed that in the 6 months prior to initiating antiretroviral therapy, alcohol use (adjusted odds ratio [AOR] 0.32; 95% CI 0.13–0.81) and incarceration (AOR 0.22; 95% CI 0.09–0.58) were independently associated with lower odds of HIV-1 RNA suppression. Factors positively associated with HIV-1 RNA suppression included: adherence (AOR 1.27; 95% CI 1.06–1.51); lower baseline HIV-1 RNA (AOR 1.30: 95% CI 1.01–1.66); highly active antiretroviral therapy (AOR 4.10; 95% CI 1.56–10.6); months on therapy (AOR 1.1; 95% CI 1.06–1.14). Among HIV-infected injection drug users who were on antiretroviral therapy, any alcohol use and incarceration in the 6 months prior to initiating antiretroviral therapy were negatively associated with achieving HIV-1 RNA suppression. In addition to addition treatment for active heroin and cocaine use, the identification and treatment of alcohol problems should be supported in this setting. As well, increased outreach to HIV-infected drug users recently released from prison to ensure continuity of care needs to be further developed.

Keywords: Anti-HIV agents, HIV infections, Human, Logistic regression models, Substance abuse, Intravenous, Alcohol, Prison

Full Text

The Full Text of this article is available as a PDF (74.6 KB).

References

  • 1.Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquired Immune Defic Syndromes. 2001;27(3):251–259. doi: 10.1097/00126334-200107010-00006. [DOI] [PubMed] [Google Scholar]
  • 2.Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–774. doi: 10.1097/00002030-200203290-00012. [DOI] [PubMed] [Google Scholar]
  • 3.Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–381. doi: 10.1046/j.1525-1497.2002.10644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34(4):511–518. doi: 10.1086/338400. [DOI] [PubMed] [Google Scholar]
  • 5.Maruschak LM. Bureau of Justice Statistics Bulletin: HIV in Prisons and Jails, 1999. Document NCJ 187456, 2001. Available at ojp.usdoj.gov/bjs/pub/hivpj99.pdf. Accessed November 11, 2003.
  • 6.Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11(8):F59–65. doi: 10.1097/00002030-199708000-00001. [DOI] [PubMed] [Google Scholar]
  • 7.Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280(6):547–549. doi: 10.1001/jama.280.6.547. [DOI] [PubMed] [Google Scholar]
  • 8.Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283(3):381–390. doi: 10.1001/jama.283.3.381. [DOI] [PubMed] [Google Scholar]
  • 9.Palepu A, Yip B, Miller C, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001;15(3):423–424. doi: 10.1097/00002030-200102160-00021. [DOI] [PubMed] [Google Scholar]
  • 10.Low-Beer S, Yip B, O’Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response [letter] J Acquir Immune Defic Syndr. 2000;23(4):360–361. doi: 10.1097/00126334-200004010-00016. [DOI] [PubMed] [Google Scholar]
  • 11.Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–1058. doi: 10.1097/00002030-200205030-00012. [DOI] [PubMed] [Google Scholar]
  • 12.Fabris P, Tositti G, Manfrin V, et al. Does alcohol intake affect highly active antiretroviral therapy (HAART) response in HIV-positive patients. J Acquir Immune Defic Syndr. 2000;25(1):92–93. doi: 10.1097/00042560-200009010-00013. [DOI] [PubMed] [Google Scholar]
  • 13.Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80. doi: 10.1001/jama.283.1.74. [DOI] [PubMed] [Google Scholar]
  • 14.Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV cost and services utilization study. J Stud Alcohol. 2002;63(2):179–186. doi: 10.15288/jsa.2002.63.179. [DOI] [PubMed] [Google Scholar]
  • 15.Sanchez-Craig M, Wilkinson DA, Davila R. Empirically based guidelines for moderate drinking: 1-year results from 3 studies with problem drinkers. Am J Public Health. 1995;85(6):823–828. doi: 10.2105/AJPH.85.6.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Barbor TF, Fuente JR, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1992. [Google Scholar]
  • 17.Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83–88. doi: 10.1111/j.1525-1497.2001.00122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305–312. doi: 10.1086/341418. [DOI] [PubMed] [Google Scholar]
  • 19.Baillargeon J, Borucki MJ, Zepeda S, Jenson HB, Leach CT. Antiretroviral prescribing patterns in the Texas prison system. Clin Infect Dis. 2000;31(6):1476–1481. doi: 10.1086/317478. [DOI] [PubMed] [Google Scholar]
  • 20.White MC, Mehrotra A, Menendez E, Estes M, Goldenson J, Tulsky JP. Jail inmates and HIV care: provision of antiretroviral therapy and Pneumocystis carinii pneumonia prophylaxis. Int J STD AIDS. 2001;12(6):380–385. doi: 10.1258/0956462011923327. [DOI] [PubMed] [Google Scholar]
  • 21.Kim JY, Rich J, Zeiler S, et al. Successful community follow-up and reduced recidivism of HIV positive women prisoners. J Correctional Health Care. 1997;4:1–9. [Google Scholar]
  • 22.Stein MD, Urdaneta ME, Clarke J, et al. Use of antiretroviral therapies by HIV-infected persons receiving methadone maintenance. J Addictive Dis. 2000;19(1):85–94. doi: 10.1300/J069v19n01_07. [DOI] [PubMed] [Google Scholar]
  • 23.Clarke SM, Mulcahy FM. Antiretroviral therapy for drug users. Int J STD AIDS. 2000;11(10):627–631. doi: 10.1258/0956462001914913. [DOI] [PubMed] [Google Scholar]
  • 24.Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–1715. doi: 10.1097/00002030-200109070-00015. [DOI] [PubMed] [Google Scholar]
  • 25.Turner BJ, Zhang D, Laine C, Pomerantz RJ, Cosler L, Hauck WW. Association of provider and patient characteristics with HIV-infected women’s antiretroviral therapy regimen. J Acquir Immune Defic Syndr. 2001;27(1):20–29. doi: 10.1097/00126334-200105010-00004. [DOI] [PubMed] [Google Scholar]
  • 26.Stein MD, Rich JD, Maksad J, et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse. 2000;26(2):195–205. doi: 10.1081/ADA-100100600. [DOI] [PubMed] [Google Scholar]
  • 27.Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999;13(8):957–962. doi: 10.1097/00002030-199905280-00012. [DOI] [PubMed] [Google Scholar]
  • 28.Geletko SM, Erickson AD. Decreased methadone effect after ritonavir initiation. Pharmacotherapy. 2000;20(1):93–94. doi: 10.1592/phco.20.1.93.34654. [DOI] [PubMed] [Google Scholar]
  • 29.Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51(3):213–217. doi: 10.1046/j.1365-2125.2001.00342.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gerber JG, Rosenkranz S, Segal Y, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J Acquir Immune Defic Syndr. 2001;27(2):153–160. doi: 10.1097/00126334-200106010-00010. [DOI] [PubMed] [Google Scholar]
  • 31.Carrieri MP, Vlahov D, Dellamonica P, et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug Alcohol Depend. 2000;60(1):51–54. doi: 10.1016/S0376-8716(99)00136-2. [DOI] [PubMed] [Google Scholar]
  • 32.Turner BJ, Newschaffer CJ, Zhang D, Cosler L, Hauck WW. Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women. Med Care. 2000;38(9):911–925. doi: 10.1097/00005650-200009000-00005. [DOI] [PubMed] [Google Scholar]
  • 33.Raboud JM, Rae S, Vella S, et al. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. J Acquir Immune Defic Syndr. 1999;22(3):260–266. doi: 10.1097/00126334-199911010-00007. [DOI] [PubMed] [Google Scholar]
  • 34.Havlir D, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286(2):171–179. doi: 10.1001/jama.286.2.171. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES